This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Safety' To characterize the safety and tolerability of a single dose of the adenoviral vector vaccine delivered at each of two escalating doses (1010 PU and 1011 PU IM) in participants with low (<1:12) titers of pre-existing Ad5 neutralizing antibodies.Secondary objectivesImmunogenicity' To evaluate the HIV-specific immunogenicity, as assessed by IFN-? ELISpot, ICS, ELISA for HIV-1-binding antibodies, and neutralizing antibody assays, of a single dose of the adenoviral vector vaccine delivered at each of two escalating doses (1010 PU and 1011 PU IM) in participants with low (<1:12) titers of pre-existing neutralizing antibodies to Ad5.' Assess the magnitude of Ad5 neutralizing antibodies induced by the study vaccine.' Assess the association between post-vaccine Ad5 neutralizing antibody titer and magnitude of HIV-1-specific immune reponses (IFN-? ELISpot, ICS, and HIV-1 neutralizing antibodies) induced by the study vaccine.Social impacts' To evaluate the social impacts of trial participation.
Showing the most recent 10 out of 515 publications